Pathogenesis, diagnosis, and treatment of alcoholic liver disease

Mayo Clinic Proceedings

Volumn 76, Issue 10, 2001, Pages 1021-1029

  Menon, K V N ^a   Gores, G J ^a   Shah, V H ^a  

^a MAYO CLINIC   (United States)

Author keywords

ALT = alanine aminotransferase; AST = aspartate aminotransferase; CAGE = alcoholism screening tool containing 4 structured questions; DF = discriminant function; GI = gastrointestinal; MCV = mean corpuscular volume; NF B = nuclear factor B; TNF = tumor necrosis factor

Indexed keywords

ANTIINFECTIVE AGENT; ANTIOXIDANT; COLCHICINE; CORTICOSTEROID; GLUCAGON; INSULIN; PHOSPHATIDYLCHOLINE; S ADENOSYLMETHIONINE; SILYMARIN; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; CLINICAL EXAMINATION; COLLAGEN DEGRADATION; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; FATTY LIVER; HUMAN; INFECTION; LABORATORY TEST; LIVER BIOPSY; LIVER REGENERATION; LIVER TRANSPLANTATION; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PATHOGENESIS; PHYSICAL EXAMINATION; REVIEW;

EID: 0034784358     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.10.1021     Document Type: Review

References (74)

1. Alcohol consumption and alcoholic liver disease: Evidence of a threshold level of effects of ethanol
2. Prediction of risk of liver disease by alcohol intake, sex, and age: A prospective population study
3. Increased susceptibility to liver disease in relation to alcohol consumption in women
4. Sex-related differences among 100 patients with alcoholic liver disease
5. Alcoholic liver disease
6. Medical disorders of alcoholism
7. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis
8. Hepatitis C virus antibodies in chronic alcoholic patients: Association with severity of liver injury
9. Excess weight risk factor for alcoholic liver disease
10. Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics
11. Old and new MMPI-derived scales and the short-MAST as screening tools for alcohol disorder
12. The validity of the Michigan Alcoholism Screening Test (MAST)
13. Screening for alcohol abuse using CAGE scores and likelihood ratios
14. Influence of age, alcohol consumption and abstinence on the sensitivity of carbohydrate-deficient transferrin, gamma-glutamyltransferase and mean corpuscular volume
15. New diagnostic markers of alcohol abuse
16. Relative versus absolute carbohydrate-deficient transferrin as a marker of alcohol consumption in patients with acute alcoholic hepatitis
17. Carbohydrate-deficient transferrin as compared to other markers of alcoholism: A systematic review
18. Carbohydrate-deficient transferrin: Diagnostic efficiency among patients with end-stage liver disease before and after liver transplantation
19. The ratio of aspartate aminotrans- ferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease
20. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis
21. Assessment of prognostic factors in alcoholic liver disease: Toward a global quantitative expression of severity
22. A comparison between clinical diagnosis and histopathological findings in liver biopsies
23. Nonalcoholic liver disease: Overlooked causes of liver injury in patients with heavy alcohol consumption
24. Should we routinely perform liver biopsy in suspected alcoholic liver disease?
25. Alcoholic liver disease: Proposed recommendations for the American College of Gastroenterology
26. The treatment of alcoholic hepatitis
27. Natural history of alcoholic hepatitis. II: The long-term prognosis
28. Duration of survival in patients with Laennec's cirrhosis: Influence of alcohol withdrawal. And possible effects of recent changes in general management of the disease
29. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis
30. Liver transplantation for alcoholic liver disease at King's College Hospital: Survival and quality of life
31. Issues in selection for and outcome of liver transplantation in patients with alcoholic liver disease
32. Liver transplantation for alcoholic liver disease: Executive statement and recommendations: Summary of a National Institutes of Health workshop held December 6-7 1996
33. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials
34. Glucocorticoids are ineffective in alcoholic hepatitis: A meta-analysis adjusting for confounding variables
35. Adrenocorticosteroid therapy in alcoholic hepatitis: A prospective, double-blind randomized study
36. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis: With a note on published results in encephalopathic patients
37. Prednisone therapy of acute alcoholic hepatitis: Report of a controlled trial
38. Corti-costeroid therapy in severe alcoholic hepatitis: A double-blind drug trial
39. Treatment of alcoholic hepatitis with encephalopathy: Comparison of prednisolone with caloric supplements
40. Alcoholic hepatitis: Natural history and evaluation of prednisolone therapy
41. Steroid treatment of alcoholic hepatitis: The yeas and the nays
42. Corticosteroid therapy of alcoholic hepatitis
43. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone
44. Methylprednisolone therapy in patients with severe alcoholic hepatitis: A randomized multicenter trial
45. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone
46. Anti-oxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro
47. Tumor necrosis factor and alcoholic liver disease
48. Death receptors in liver biology and patho-biology
49. Apoptosis and alcoholic liver disease
50. The tumor necrosis factor ligand and receptor families
51. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor
52. Is apoptosis involved in alcoholic hepatitis?
53. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage
54. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis
55. Tumor necrosis factor, the acute phase response and the pathogenesis of alcoholic liver disease
56. Increased plasma tumor necrosis factor in severe alcoholic hepatitis
57. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis
58. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis
59. Anti-bodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat
60. Pentoxifylline improves short-term survival in severe acute alco- holic hepatitis: A double-blind, placebo-controlled trial
61. TNF-α is not the cause of fatty liver disease in obese diabetic mice
62. Increased plasma interleukin-6 concentrations in alcoholic hepatitis
63. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease
64. Apoptosis and liver disease
65. Alcoholic liver disease: New insights in pathogenesis lead to new treatments
66. Chronic ethanol consumption alters rat liver plasma membranes and potentiates release of alka-line phosphatase
67. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease
68. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis
69. S-adenosyl-methionine in alcoholic liver cirrhosis: A randomized placebo-controlled, double-blind, multicenter clinical trial
70. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial
71. Alcohol and liver regeneration
72. Acetaldehyde and alcoholic fibrogenesis: Fuel to the fire, but not the spark
73. Colchicine in the treatment of cirrhosis of the liver
74. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis